Brepocitinib
- Generic Name
- Brepocitinib
A 12-Week Open-Label Study to Investigate the Efficacy and Safety of Brepocitinib in Adults With Skin-Predominant Dermatomyositis
- First Posted Date
- 2024-05-30
- Last Posted Date
- 2025-05-20
- Lead Sponsor
- Priovant Therapeutics, Inc.
- Target Recruit Count
- 5
- Registration Number
- NCT06433999
- Locations
- 🇺🇸
Clinical Trial Site, Scottsdale, Arizona, United States
A Study of Brepocitinib in Adults with Active Non-Infectious Non-Anterior Uveitis
Phase 2
Completed
- Conditions
- Non-infectious Pan UveitisNon-infectious Intermediate UveitisNon-infectious Posterior Uveitis
- Interventions
- First Posted Date
- 2022-08-31
- Last Posted Date
- 2024-11-26
- Lead Sponsor
- Priovant Therapeutics, Inc.
- Target Recruit Count
- 26
- Registration Number
- NCT05523765
- Locations
- 🇺🇸
Clinical Trial Site, Salt Lake City, Utah, United States
A Study to Investigate the Efficacy and Safety of Brepocitinib in Adults with Dermatomyositis
- First Posted Date
- 2022-06-29
- Last Posted Date
- 2024-11-27
- Lead Sponsor
- Priovant Therapeutics, Inc.
- Target Recruit Count
- 241
- Registration Number
- NCT05437263
- Locations
- 🇬🇧
Clinical Trial Site, Wolverhampton, United Kingdom
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath